Dexrazoxane study to monitor heart damage in cancer survivors
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests dexrazoxane (DRZ) to see how it affects blood and heart-related “biomarkers,” or measurable signs of heart damage, after cancer treatment. It mainly targets survivors who may be at risk for cardiomyopathy (heart muscle weakness) or related heart failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must fall into the study’s open group, Stratum IV (current stratum for new records), if Strata I–III are closed to new entries
- You had cancer before age 21, were treated with chemotherapy and/or radiation, and have been in remission for at least 1 year
- You have echocardiogram (heart ultrasound) images available in the required digital format (DICOM)
- You do not have a known congenital heart disease (a specific common one, patent foramen ovale, is allowed) or a genetic condition linked to heart development problems
- Your heart ultrasound shows reduced heart pumping on at least two checks (or one check plus ongoing heart medicine for at least 6 months)
- You (and your parent/guardian, if needed) must be able to provide informed consent or have required record-based permissions for the specific stratum
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests DCSZ11 in people with advanced or metastatic solid tumors (cancers that can’t be removed or have spread) given alone or with other treatments. It’s designed to find a safe dose and to see whether the treatment shows signs of shrinking cancer.
This Phase 2 study tests dexrazoxane, a heart-protecting medicine, to reduce heart side effects from chemotherapy in people with certain blood cancers. If you qualify, you would receive dexrazoxane along with chemotherapy, and the team will monitor your heart function closely.
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
This trial tests if the drug dexrazoxane can protect the heart during chemotherapy for a type of lymphoma called DLBCL. It may be an option for patients starting a standard treatment regimen known as R-CHOP.
This study allows people who are already in a Daiichi Sankyo trial and getting benefit from the study drug to continue receiving it safely. It monitors long-term safety for those who have not had their cancer worsen.
This trial tests new drugs for people with advanced squamous non-small cell lung cancer that has gotten worse after standard treatments like immunotherapy and chemotherapy. The goal is to find better options for those who need them.
Hear when a new Lymphoblastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.